SAN FRANCISCO (AP) _ Nektar Therapeutics (NKTR) on Thursday reported a loss of $112.2 million in its fourth quarter.
On a per-share basis, the San Francisco-based company said it had a loss of 64 cents.
The results exceeded Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for a loss of 69 cents per share.
The biopharmaceutical company posted revenue of $33.9 million in the period, also exceeding Street forecasts. Seven analysts surveyed by Zacks expected $26.3 million.
For the year, the company reported a loss of $440.7 million, or $2.52 per share, swinging to a loss in the period. Revenue was reported as $114.6 million.
Nektar shares have decreased roughly 5% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $20.53, a drop of 50% in the last 12 months.